BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 17656559)

  • 1. Potential clinical applications of epothilones: a review of phase II studies.
    Larkin JM; Kaye SB
    Ann Oncol; 2007 Jul; 18 Suppl 5():v28-34. PubMed ID: 17656559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epothilones in prostate cancer: review of clinical experience.
    Dawson NA
    Ann Oncol; 2007 Jul; 18 Suppl 5():v22-7. PubMed ID: 17656558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues.
    Fumoleau P; Coudert B; Isambert N; Ferrant E
    Ann Oncol; 2007 Jul; 18 Suppl 5():v9-15. PubMed ID: 17656562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epothilones in breast cancer: review of clinical experience.
    Fornier MN
    Ann Oncol; 2007 Jul; 18 Suppl 5():v16-21. PubMed ID: 17656557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epothilones in the treatment of cancer.
    Larkin JM; Kaye SB
    Expert Opin Investig Drugs; 2006 Jun; 15(6):691-702. PubMed ID: 16732719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The epothilones: how pharmacology relates to clinical utility.
    Michaud LB
    Ann Pharmacother; 2009 Jul; 43(7):1294-309. PubMed ID: 19584389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the microtubules in breast cancer beyond taxanes: the epothilones.
    Cortes J; Baselga J
    Oncologist; 2007 Mar; 12(3):271-80. PubMed ID: 17405891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epothilones: tubulin polymerization as a novel target for prostate cancer therapy.
    Lee JJ; Kelly WK
    Nat Clin Pract Oncol; 2009 Feb; 6(2):85-92. PubMed ID: 19048010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epothilones in the treatment of ovarian cancer.
    Diaz-Padilla I; Oza AM
    Future Oncol; 2011 Apr; 7(4):559-68. PubMed ID: 21463144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel cytotoxic agents: epothilones.
    Goodin S
    Am J Health Syst Pharm; 2008 May; 65(10 Suppl 3):S10-5. PubMed ID: 18463327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes.
    Yardley DA
    Clin Breast Cancer; 2008 Dec; 8(6):487-92. PubMed ID: 19073502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.
    Trivedi M; Budihardjo I; Loureiro K; Reid TR; Ma JD
    Future Oncol; 2008 Aug; 4(4):483-500. PubMed ID: 18684060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experience with epothilones in patients with breast cancer.
    Buzdar AU
    Clin Breast Cancer; 2008 Mar; 8 Suppl 2():S71-8. PubMed ID: 18637402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epothilones: clinical update and future directions.
    Donovan D; Vahdat LT
    Oncology (Williston Park); 2008 Apr; 22(4):408-16; discussion 416, 421, 424 passim. PubMed ID: 18472615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of other microtubule-stabilizer families: the epothilones and their derivatives.
    Brogdon CF; Lee FY; Canetta RM
    Anticancer Drugs; 2014 May; 25(5):599-609. PubMed ID: 24398663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
    Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patupilone in cancer treatment.
    Bystricky B; Chau I
    Expert Opin Investig Drugs; 2011 Jan; 20(1):107-17. PubMed ID: 21142807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors.
    Rivera E; Lee J; Davies A
    Oncologist; 2008 Dec; 13(12):1207-23. PubMed ID: 19088324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms.
    Vahdat L
    Oncologist; 2008 Mar; 13(3):214-21. PubMed ID: 18378531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ixabepilone for the treatment of solid tumors: a review of clinical data.
    Denduluri N; Swain SM
    Expert Opin Investig Drugs; 2008 Mar; 17(3):423-35. PubMed ID: 18321240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.